Randomized trial shows semaglutide reduces heavy drinking in adults with AUD and obesity, suggesting a new treatment approach.
Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: